Navigation Links
Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
Date:3/2/2009

rse events were CNS-related and were mild to moderate in severity. Common adverse events experienced by more than 5 percent of subjects included dizziness, fatigue, somnolence, headache, abnormal coordination, falls, nasopharyngitis (an inflammation of the nasal passages) and convulsion. No deaths were reported in this study.

All patients completing the double blind portion were eligible to enter an open label extension trial, with 95 percent of patients electing to continue therapy. Based on these results, Marinus is planning a dose-ranging Phase 2b program with ganaxolone.

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolone. It is being investigated as a first in class treatment for epilepsy. Ganaxolone has been administered to more than 950 healthy adult volunteers and patients in more than 35 Phase 1 and Phase 2 studies. Early epilepsy studies involved more than 100 patients and generated data supportive of the efficacy and safety of ganaxolone in the treatment of both children and adults suffering from refractory epilepsy (patients who continue to have seizures despite taking multiple anticonvulsant drugs).

Marinus has successfully developed several proprietary and novel patented formulations of ganaxolone.

About Marinus Pharmaceuticals

Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. Marinus is located in Branford, Connecticut. Its investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. For additional information, please visit the company's Web site at www.marinuspharma.com.

About Epilepsy

Epile
'/>"/>

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
2. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
3. Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
4. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
5. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
6. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
7. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
8. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
9. Renhuang Pharmaceuticals, Inc. Engages New Independent Auditor
10. Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
11. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... effort by the National Institutes of Health will ... to reframe mental health research, from diagnosis to ... recently established by the National Institute of Mental ... development of the institute,s RDoC initiative. , ... accelerate the pace of research that translates basic ...
(Date:10/31/2014)... News) -- A comparison of two of the most ... gastric bypass helped patients shed more excess pounds than ... short-term complications and long-term hospitalizations. Gastric-bypass surgery makes ... your body does not absorb all the calories from ... Health. Gastric banding is a type of weight-loss procedure ...
(Date:10/31/2014)... Steven Reinberg HealthDay Reporter THURSDAY, ... increase slightly the risk of broken bones and injured joints, a ... found that among 7 percent of people who had an eczema ... joint injury and 0.6 percent had an injury that caused a ... with the skin condition had more than double the risk of ...
(Date:10/30/2014)... one day provide new treatments for injuries and damage ... , Cartilage, for example, is a hard material that ... work smoothly. UC Davis biomedical engineers, exploring ways to ... outside the body, report new developments this week in ... Sciences . , "The problem with engineered tissue is ...
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
Breaking Medicine News(10 mins):Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2
... that occurs when a joint is damaged by injury or ... it comes to the knee, that inflammation can actually interfere ... may lead to treatments for injuries or osteoarthritis in the ... are drugs that can block the action of these immune ...
... with patients reduced risk by 10% and also cut ... management provided a cost-effective way of reducing patients, overall ... to a study by researchers at Stanford University in ... professionals such as nurses and dietitians help patients manage ...
... thirds (69%) of sexually active New York City teens use ... of public high school students. But too few sexually active ... prevent unplanned pregnancies. The full report Teen Sexual Activity ... available at www.nyc.gov/html/doh/downloads/pdf/survey/survey-2007youthsex.pdf . It finds that in New ...
... postpartum depression, study suggests , , WEDNESDAY, Aug. 29 (HealthDay News) ... mother be as simple as seeing which arm she uses ... that mothers who cradle their baby on their right side ... new mothers feel some levels of stress during the first ...
... (RA), an autoimmune disease marked by chronic inflammation of ... incidence of cancer is complicated. Epidemiologic studies have ... increased among RA patients, while breast and colon cancers ... by the nature of RA or by immunosuppressive drugs ...
... study confirms , , TUESDAY, Aug. 28 (HealthDay News) -- ... go together, a new study finds that it is ... more alcohol problems a man has, the more likely ... a disadvantaged neighborhood," according to a team of University ...
Cached Medicine News:Health News:New insights into common knee injuries 2Health News:Case Management Cost-Effective Way to Cut Heart Risks 2Health News:More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag 2Health News:More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag 3Health News:Stressed-Out Moms Carry Babies on the Right 2Health News:Biologic treatment for rheumatoid arthritis and the risk of cancer 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 3
(Date:10/31/2014)... LONDON , October 31, 2014 ... (NYSE: MDT ), Abbott Laboratories (NYSE: ... Inc. (NYSE: RMD ), and Covidien PLC (NYSE: ... at: http://investor-edge.com/register . The US markets on ... the Dow Jones Industrial Average finished at 17,195.42, up 1.30% ...
(Date:10/31/2014)... Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, ... 30, 2014. Brian M. Culley, the ... productive for Mast. Consistent with prior guidance, our 388-patient pivotal ... is on track to complete enrollment by the end ... in the U.S. and more than ten study sites ...
(Date:10/31/2014)... , October 31, 2014 ... a clinical-stage pharmaceutical company focused on the development ... company will host a conference call to discuss ... trial of ORMD-0801, the company,s proprietary oral insulin ... November 3, 2014 at 10:00 a.m. Eastern time. ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
... 15, 2011 MIM Software Inc., a leading global ... MIM™ is available on the U.S. App Store. This ... the app had received 510(k) clearance for remote diagnostic ... the iPhone®, iPod touch®, and iPad®. (Photo: ...
... Fla., Feb. 15, 2011 The Florida Society of ... of Pain Medicine ( www.fapmmed.net ) and The American ... President Mike Haridopolos and Attorney General Pam Bondi for ... and their opposition to the recently announced attempt to ...
Cached Medicine Technology:Mobile MIM, First FDA-Cleared Diagnostic Medical Imaging App, Now Available on the U.S. App Store 2Mobile MIM, First FDA-Cleared Diagnostic Medical Imaging App, Now Available on the U.S. App Store 3Florida Pain Clinic Organizations Applaud FL Senate President Haridopolos and Attorney General Bondi 2
... and conveniently controls the temperature at your lab ... levels up to 99 C*, with the "plus" ... as 5 C. The thermoblocks for 0.2 ml**, ... microplates enable a high degree of flexibility for ...
... 10k units Pen.,10k ug Strept. ... Cell Culture Reagent and Buffer ... with cGMP regulations and are ... compatibility. , Typical Properties, Sterility ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
... A combination of penicillin and ... gram positive and gram negative bacteria ... of 100,000 I.U. Penicillin/100,000 g/mL Streptomycin ... prepared in water at concentrations of ...
Medicine Products: